Literature DB >> 9197261

The role of antibody concentration and avidity in antiviral protection.

M F Bachmann1, U Kalinke, A Althage, G Freer, C Burkhart, H Roost, M Aguet, H Hengartner, R M Zinkernagel.   

Abstract

Neutralizing antibodies are necessary and sufficient for protection against infection with vesicular stomatitis virus (VSV). The in vitro neutralization capacities and in vivo protective capacities of a panel of immunoglobulin G monoclonal antibodies to the glycoprotein of VSV were evaluated. In vitro, neutralizing activity correlated with avidity and with neutralization rate constant, a measure of on-rate. However, in vivo, protection was independent of immunoglobulin subclass, avidity, neutralization rate constant, and in vitro neutralizing activity; above a minimal avidity threshold, protection depended simply on a minimum serum concentration. These two biologically defined thresholds of antibody specificity offer hope for the development of adoptive therapy with neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197261     DOI: 10.1126/science.276.5321.2024

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  91 in total

1.  Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro.

Authors:  R Moreno; F Pöltl-Frank; D Stüber; H Matile; M Mutz; N A Weiss; G Pluschke
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs.

Authors:  A F Ochsenbein; D D Pinschewer; S Sierro; E Horvath; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

6.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

7.  Judging a virus by its cover.

Authors:  Eva Szomolanyi-Tsuda; Raymond M Welsh
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 8.  Immunological memory ≠ protective immunity.

Authors:  Rolf M Zinkernagel
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

Review 9.  Immunological memory: lessons from the past and a look to the future.

Authors:  Donna L Farber; Mihai G Netea; Andreas Radbruch; Klaus Rajewsky; Rolf M Zinkernagel
Journal:  Nat Rev Immunol       Date:  2016-02       Impact factor: 53.106

10.  Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.

Authors:  Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg
Journal:  J Neurol Sci       Date:  2007-06-15       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.